The frequency of CD5+ B lymphocytes in the peripheral blood of patients with myasthenia gravis
- PMID: 1694020
- DOI: 10.1212/wnl.40.7.1120
The frequency of CD5+ B lymphocytes in the peripheral blood of patients with myasthenia gravis
Abstract
A subset of human B lymphocytes expresses Leu-1 (CD5), a pan-T cell marker, which is the equivalent of the murine Lyt-1 molecule. CD5+ B cells produce autoantibodies in vitro; therefore, they may play a role in the pathogenesis of autoimmune disorders. In myasthenia gravis (MG), autoantibodies are directed against the nicotinic acetylcholine receptor (AChR) at the neuromuscular junction. We examined the peripheral blood leukocytes of MG patients (n = 21) and controls (n = 15) for the presence of Leu-1+ B lymphocytes. A fraction of B-1 (CD20)+ cells expressed Leu-1 at a low density. There was a statistically significant difference in the frequency of Leu-1+ B cells between patients and controls. We observed 2 frequency ranges of Leu-1+ B cells (0 to 30% and above 30%), which were not related to the total percentage of B-1+ cells in the blood. Fifty-seven percent of MG patients had a high frequency of Leu-1+ B cells compared with 13% of controls.
Similar articles
-
Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients.J Neurol. 1996 Jan;243(1):57-62. doi: 10.1007/BF00878532. J Neurol. 1996. PMID: 8869388
-
The CD5+ B cells and myasthenia gravis.Autoimmunity. 1995;20(2):129-34. doi: 10.3109/08916939509001937. Autoimmunity. 1995. PMID: 7578869
-
Effect of clinical status and treatment on the frequency of CD5+ B cells in patients with myasthenia gravis.Neurology. 1992 May;42(5):1076-80. doi: 10.1212/wnl.42.5.1076. Neurology. 1992. PMID: 1374546
-
The importance of CD5-positive B cells in nonorgan-specific autoimmune diseases.Scand J Rheumatol Suppl. 1988;76:243-9. doi: 10.3109/03009748809102975. Scand J Rheumatol Suppl. 1988. PMID: 2471999 Review.
-
On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.Crit Rev Immunol. 2001;21(1-3):1-27. Crit Rev Immunol. 2001. PMID: 11642597 Review.
Cited by
-
Pathological Findings in Myasthenia Gravis Patients with Thymic Hyperplasia and Thymoma.Pathol Oncol Res. 2018 Jan;24(1):67-74. doi: 10.1007/s12253-017-0213-7. Epub 2017 Mar 15. Pathol Oncol Res. 2018. PMID: 28299711
-
CD5 expression on B cells may be an activation marker for secretion of anti-myelin antibodies in patients with polyneuropathy associated with monoclonal gammopathy.Clin Exp Immunol. 1995 Aug;101(2):346-50. doi: 10.1111/j.1365-2249.1995.tb08362.x. Clin Exp Immunol. 1995. PMID: 7544252 Free PMC article.
-
Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients.J Neurol. 1996 Jan;243(1):57-62. doi: 10.1007/BF00878532. J Neurol. 1996. PMID: 8869388
-
B cells in the pathophysiology of myasthenia gravis.Muscle Nerve. 2018 Feb;57(2):172-184. doi: 10.1002/mus.25973. Epub 2017 Sep 30. Muscle Nerve. 2018. PMID: 28940642 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical